Completed PHASE1 INTERVENTIONAL 2-arm NCT01247272

90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions

A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions

Sponsor: Teva Pharmaceuticals USA

Conditions Healthy

Interventions Fluoxetine Hydrochloride PROZAC WEEKLY®

Updated 8 times since 2017 Last updated: Jan 24, 2011 Started: May 31, 2001 Primary completion: Jul 31, 2001 Completion: Jul 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Teva Pharmaceuticals USA and has accumulated 8 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teva Pharmaceuticals USA

Data source: Teva Pharmaceuticals USA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fargo, United States